WCA
KNSA icon

Windsor Creek Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Windsor Creek Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,268
Closed -$252K – 195
2020
Q4 		$252K Hold
14,268
– – 0.06% 161
2020
Q3 		$219K Buy
+14,268
New +$268K 0.06% 151

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Windsor Creek Advisors's KNSA Position: Q1 2021 in Review

Windsor Creek Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2021, closing a stake of 14,268 shares — an estimated $252K sold.

Windsor Creek Advisors first reported a position in KNSA in Q3 2020 and held it in 2 quarters. The position peaked at $252K in Q4 2020. 105 funds tracked by Wall St. Rank hold KNSA as of Q1 2021.

  • Windsor Creek Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Windsor Creek Advisors sold 14,268 Kiniksa Pharmaceuticals shares in Q1 2021, an estimated $252K.
  • Windsor Creek Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Windsor Creek Advisors's Kiniksa Pharmaceuticals position peaked at $252K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2021.

Based on Windsor Creek Advisors's 13F filing for Q1 2021, filed 13 May 2021.